BioCentury
ARTICLE | Financial News

HiFiBiO’s $67M series C attracts Kite, international syndicate

August 28, 2019 11:06 PM UTC

As it seeks to expand its platform and further develop its pipeline of antibodies for cancer and autoimmune disease, HiFiBiO raised $67 million in a series C led by new investor IDG Capital.

HiFiBiO Therapeutics (Cambridge, Mass.) uses its CelliGo platform to analyze the full repertoire of B cells a person generates in response to an antigen in order to screen antibodies for functional activity. It aims to improve the odds of finding a viable therapeutic by rapidly producing large, genetically diverse sets of functional antibodies (see "Mining for Functionality")...

BCIQ Company Profiles

HiFiBiO Inc.

Kite Pharma Inc.